Last 12 months
Inside the activity.
0 purchase rows · 57 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 16 |
| Dec 2025 | 0 | 12 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 8 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 4 |
| Jun 2026 | 0 | 8 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 9 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 5,313 | $9.05 Strike: $9.05 | $48,082.65 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · derivative · entry 9 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,250 Underlying: Common Stock · 5,313 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F6 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 1,563 | $5.43 Strike: $5.43 | $8,487.09 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · derivative · entry 8 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 522 Underlying: Common Stock · 1,563 shares Expires 2026-03-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F5 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 15, 2017, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 3,750 | $6.45 Strike: $6.45 | $24,187.50 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · derivative · entry 7 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2 Underlying: Common Stock · 3,750 shares Expires 2026-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F4 · derivative.exercise_date: The option is fully vested. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 2,339 | $25.91 | $60,592.03 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 6 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,274 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F3 · price: Represents weighted average sales price. Sale prices for the transactions range from $25.78 to $26.05. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
SaleCommon Stock | 30,542 | $25.35 | $774,206.10 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 5 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,613 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $24.77 to $25.75. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 4,407 | $5.98 | $26,353.86 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 4 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,155 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 5,313 | $9.05 | $48,082.65 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,748 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 1,563 | $5.43 | $8,487.09 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| March 03, 2020 Filed Mar 4, 2020 22:49 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Exercise / conversionCommon Stock | 3,750 | $6.45 | $24,187.50 |
DisclosureSEC source: 0001384101-20-000039 · wf-form4_158336213084937.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,872 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on May 3, 2019. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 23:00 UTC |
Ho MarkPrincipal Accounting Officer
|
Tax withholdingCommon Stock | 486 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000037 · wf-form4_158327640113532.xml · nonDerivative · entry 2 Ho Mark · CIK 0001554165 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,419 F3 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:58 UTC |
Hanna John Walter JRChief Commercial Officer
|
Tax withholdingCommon Stock | 997 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000035 · wf-form4_158327630587282.xml · nonDerivative · entry 2 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,472 F3 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:51 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 4,937 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000029 · wf-form4_158327587188563.xml · nonDerivative · entry 2 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,313 F2 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:53 UTC |
Kennedy KeithCOO / CFO
|
Tax withholdingCommon Stock | 1,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000031 · wf-form4_158327596412675.xml · nonDerivative · entry 2 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 158,007 F2 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| March 02, 2020 Filed Mar 3, 2020 22:55 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Tax withholdingCommon Stock | 896 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000033 · wf-form4_158327613077235.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,122 F2 · kind: Shares relinquished by the Reporting Person and cancelled by the Issuer in exchange for the Issuer's agreement to pay federal and state tax withholding obligations of the Reporting Person resulting from the vesting of restricted stock units. The Reporting Person did not sell or otherwise dispose of the shares for any reason other than to cover required taxes. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:00 UTC |
Ho MarkPrincipal Accounting Officer
|
GrantStock Option (right to buy) · Derivative | 17,500 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001384101-20-000037 · wf-form4_158327640113532.xml · derivative · entry 3 Ho Mark · CIK 0001554165 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Underlying: Common Stock · 17,500 shares Expires 2030-02-27 F4 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 23:00 UTC |
Ho MarkPrincipal Accounting Officer
|
GrantCommon Stock | 3,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000037 · wf-form4_158327640113532.xml · nonDerivative · entry 1 Ho Mark · CIK 0001554165 · Principal Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,905 F1 · kind: Restricted stock units awarded on February 28, 2020 vest 25% on March 2, 2021 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. F2 · balance_after: Includes 1,147 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:58 UTC |
Hanna John Walter JRChief Commercial Officer
|
GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001384101-20-000035 · wf-form4_158327630587282.xml · derivative · entry 4 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-02-27 F4 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:58 UTC |
Hanna John Walter JRChief Commercial Officer
|
GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000035 · wf-form4_158327630587282.xml · nonDerivative · entry 1 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,469 F1 · kind: Restricted stock units awarded on February 28, 2020 vest 25% on March 2, 2021 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. F2 · balance_after: Includes 1,194 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:51 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
GrantStock Option (right to buy) · Derivative | 192,500 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001384101-20-000029 · wf-form4_158327587188563.xml · derivative · entry 4 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 192,500 Underlying: Common Stock · 192,500 shares Expires 2030-02-27 F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:51 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
GrantCommon Stock | 33,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000029 · wf-form4_158327587188563.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,250 F1 · kind: Restricted stock units awarded on February 28, 2020 which vest 25% on March 2, 2021 and 1/16 per quarter thereafter, based on continuing services on each vesting date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:53 UTC |
Kennedy KeithCOO / CFO
|
GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001384101-20-000031 · wf-form4_158327596412675.xml · derivative · entry 3 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-02-27 F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:53 UTC |
Kennedy KeithCOO / CFO
|
GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000031 · wf-form4_158327596412675.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,400 F1 · kind: Restricted stock units awarded on February 28, 2020 vest 25% on March 2, 2021 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:55 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $24.69 | $0.00 |
DisclosureSEC source: 0001384101-20-000033 · wf-form4_158327613077235.xml · derivative · entry 3 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2030-03-27 F3 · derivative.exercise_date: The option becomes exercisable as to 25% of the shares on February 28, 2021, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
| February 28, 2020 Filed Mar 3, 2020 22:55 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
GrantCommon Stock | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000033 · wf-form4_158327613077235.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,018 F1 · kind: Restricted stock units awarded on February 28, 2020 vest 25% on March 2, 2021 and 1/16 per quarter thereafter subject to continuing employment of the Reporting Person on each vesting date. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:17 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
Tax withholdingCommon Stock | 8,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000025 · wf-form4_158275182062299.xml · nonDerivative · entry 2 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,018 F2 · kind: The reporting person is reporting the withholding of 8,844 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 25,000 Performance Stock Units vested on February 24, 2020 and does not represent a sale by the reporting person. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:17 UTC |
Kennedy Giulia CChief Scientific & Med Officer
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000025 · wf-form4_158275182062299.xml · nonDerivative · entry 1 Kennedy Giulia C · CIK 0001769333 · Chief Scientific & Med Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,862 F1 · kind: Represents the acquisition of restricted stock units ("RSUs") earned by the Reporting Person upon the achievement of performance goals for the one-year period ended December 31, 2019, as reflected in the financial statements certified by the Audit Committee of the Board of Directors on February 24, 2020. The RSUs vested as to 50% of the total RSUs earned on February 24, 2020, and the remaining 50% of the RSUs will vest on February 24, 2021, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:15 UTC |
Kennedy KeithCOO / CFO
|
Tax withholdingCommon Stock | 13,163 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000023 · wf-form4_158275169815441.xml · nonDerivative · entry 2 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,400 F3 · kind: The reporting person is reporting the withholding of 13,163 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 25,000 Performance Stock Units vested on February 24, 2020 and does not represent a sale by the reporting person. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:15 UTC |
Kennedy KeithCOO / CFO
|
GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000023 · wf-form4_158275169815441.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,563 F1 · kind: Represents the acquisition of restricted stock units ("RSUs") earned by the Reporting Person upon the achievement of performance goals for the one-year period ended December 31, 2019, as reflected in the financial statements certified by the Audit Committee of the Board of Directors on February 24, 2020. The RSUs vested as to 50% of the total RSUs earned on February 24, 2020, and the remaining 50% of the RSUs will vest on February 24, 2021, subject to the Reporting Person's continuous service to the Issuer through such date. F2 · balance_after: Includes 860 shares of common stock purchased pursuant to the Veracyte, Inc. Employee Stock Purchase Plan on January 31, 2020. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:13 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Tax withholdingCommon Stock | 39,488 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000021 · wf-form4_158275155976931.xml · nonDerivative · entry 2 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,250 F2 · kind: The reporting person is reporting the withholding of 39,488 shares of common stock to satisfy the reporting person's tax withholding obligations in connection with the vesting of 75,000 Performance Stock Units vested on February 24, 2020 and does not represent a sale by the reporting person. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:13 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000021 · wf-form4_158275155976931.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,738 F1 · kind: Represents the acquisition of restricted stock units ("RSUs") earned by the Reporting Person upon the achievement of performance goals for the one-year period ended December 31, 2019, as reflected in the financial statements certified by the Audit Committee of the Board of Directors on February 24, 2020. The RSUs vested as to 50% of the total RSUs earned on February 24, 2020, and the remaining 50% of the RSUs will vest on February 24, 2021, subject to the Reporting Person's continuous service to the Issuer through such date. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 21:25 UTC |
JONES EVAN/ FADirector
|
SaleCommon Stock | 14,049 | $30.11 | $422,974.65 |
DisclosureSEC source: 0001384101-20-000008 · wf-form4_157964189937684.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 139,653 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.19. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 21:23 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionStock Option (right to buy) · Derivative | 7,052 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001384101-20-000006 · wf-form4_157964179339719.xml · derivative · entry 3 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,390 Underlying: Common Stock · 7,052 shares Expires 2026-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F3 · derivative.exercise_date: The option began to vest on December 6, 2017 and vests at a rate of 1/36th per total number of shares subject to the award each month, subject to the continuing employment of the reporting person on the vesting date. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 21:23 UTC |
Kennedy KeithCOO / CFO
|
SaleCommon Stock | 7,052 | $30.08 | $212,104.41 |
DisclosureSEC source: 0001384101-20-000006 · wf-form4_157964179339719.xml · nonDerivative · entry 2 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,703 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.21. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| January 16, 2020 Filed Jan 21, 2020 21:23 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionCommon Stock | 7,052 | $7.47 | $52,678.44 |
DisclosureSEC source: 0001384101-20-000006 · wf-form4_157964179339719.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,755 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| January 14, 2020 Filed Jan 15, 2020 21:54 UTC |
JONES EVAN/ FADirector
|
SaleCommon Stock | 300 | $28.93 | $8,679.99 |
DisclosureSEC source: 0001384101-20-000004 · wf-form4_157912522352347.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 153,702 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.91 to $28.95. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| January 14, 2020 Filed Jan 15, 2020 21:54 UTC |
JONES EVAN/ FADirector
|
SaleCommon Stock | 4,700 | $28.48 | $133,841.43 |
DisclosureSEC source: 0001384101-20-000004 · wf-form4_157912522352347.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 154,002 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $27.91 to $28.87. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 21:23 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001384101-20-000002 · wf-form4_157895057977644.xml · derivative · entry 4 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,241 Underlying: Common Stock · 20,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 21:23 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
SaleCommon Stock | 20,000 | $28.86 | $577,276.00 |
DisclosureSEC source: 0001384101-20-000002 · wf-form4_157895057977644.xml · nonDerivative · entry 2 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,738 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.62 to $29.15. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| January 10, 2020 Filed Jan 13, 2020 21:23 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 20,000 | $4.00 | $80,000.00 |
DisclosureSEC source: 0001384101-20-000002 · wf-form4_157895057977644.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 21:09 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionStock Option (right to buy) · Derivative | 400 | $0.00 Strike: $7.47 | $0.00 |
DisclosureSEC source: 0001384101-19-000170 · wf-form4_157782652135141.xml · derivative · entry 3 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,442 Underlying: Common Stock · 400 shares Expires 2026-12-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F3 · derivative.exercise_date: The option began to vest on December 6, 2017 and vests at a rate of 1/36th of the total number of shares subject to the award each month, subject to the continuing employment of the reporting person on each vesting date. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 21:09 UTC |
Kennedy KeithCOO / CFO
|
SaleCommon Stock | 400 | $30.00 | $12,001.96 |
DisclosureSEC source: 0001384101-19-000170 · wf-form4_157782652135141.xml · nonDerivative · entry 2 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,703 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.02. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 27, 2019 Filed Dec 31, 2019 21:09 UTC |
Kennedy KeithCOO / CFO
|
Exercise / conversionCommon Stock | 400 | $7.47 | $2,988.00 |
DisclosureSEC source: 0001384101-19-000170 · wf-form4_157782652135141.xml · nonDerivative · entry 1 Kennedy Keith · CIK 0001543503 · COO / CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,103 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| December 17, 2019 Filed Dec 18, 2019 21:37 UTC |
JONES EVAN/ FADirector
|
SaleCommon Stock | 15,000 | $29.26 | $438,865.50 |
DisclosureSEC source: 0001384101-19-000168 · wf-form4_157670504870918.xml · nonDerivative · entry 1 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 158,702 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.97 to $29.54. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:46 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $2.68 | $0.00 |
DisclosureSEC source: 0001384101-19-000166 · wf-form4_157610076486955.xml · derivative · entry 6 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,313 Underlying: Common Stock · 15,000 shares Expires 2022-03-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:46 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $4.00 | $0.00 |
DisclosureSEC source: 0001384101-19-000166 · wf-form4_157610076486955.xml · derivative · entry 5 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,241 Underlying: Common Stock · 20,000 shares Expires 2023-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F3 · derivative.exercise_date: The option is fully vested. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:46 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 15,000 | $2.68 | $40,200.00 |
DisclosureSEC source: 0001384101-19-000166 · wf-form4_157610076486955.xml · nonDerivative · entry 3 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 117,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:46 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
SaleCommon Stock | 20,000 | $28.96 | $579,248.00 |
DisclosureSEC source: 0001384101-19-000166 · wf-form4_157610076486955.xml · nonDerivative · entry 2 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,738 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. F2 · price: Represents weighted average sales price. Sale prices for the transactions range from $28.27 to $29.25. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. Read SEC document |
| December 10, 2019 Filed Dec 11, 2019 21:46 UTC |
Anderson Bonnie HDirector · Chairman and CEO
|
Exercise / conversionCommon Stock | 20,000 | $4.00 | $80,000.00 |
DisclosureSEC source: 0001384101-19-000166 · wf-form4_157610076486955.xml · nonDerivative · entry 1 Anderson Bonnie H · CIK 0001588970 · Director · Chairman and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,738 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 2, 2019. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 21:19 UTC |
JONES EVAN/ FADirector
|
SaleCommon Stock | 800 | $30.03 | $24,022.48 |
DisclosureSEC source: 0001384101-19-000164 · wf-form4_157592633992380.xml · nonDerivative · entry 2 JONES EVAN/ FA · CIK 0001020741 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · by jVen Capital, LLC Disclosed balance after: 173,702 F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 20, 2019. F4 · price: Represents weighted average sales price. Sale prices for the transactions range from $30.00 to $30.06. Detailed information regarding the number of shares sold at each separate price will be provided to the SEC, the issuer or a shareholder upon request. F3 · ownership.nature: The Reporting Person is the sole managing member of jVen Capital, LLC. Read SEC document |
| December 06, 2019 Filed Dec 9, 2019 21:17 UTC |
Hanna John Walter JRChief Commercial Officer
|
Exercise / conversionStock Option (right to buy) · Derivative | 9,838 | $0.00 Strike: $9.05 | $0.00 |
DisclosureSEC source: 0001384101-19-000162 · wf-form4_157592621292255.xml · derivative · entry 6 Hanna John Walter JR · CIK 0001781127 · Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,792 Underlying: Common Stock · 9,838 shares Expires 2027-03-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transactions on this Form 4 were made pursuant to a Rule 10b5-1 plan adopted by the reporting person on August 14, 2019. F4 · derivative.exercise_date: The option became exercisable as to 25% of the shares on March 3, 2018, and the remaining shares vest at a rate of 1/48th of the total number of shares subject to the award for each month of continuous service thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.